| 期刊論文| 1. | Cohen, M. H.、Johnson, J. R.、Chen, Y. F.、Sridhara, R.、Pazdur, R.(2005)。FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets。The Oncologist，10，461-466。   | | 2. | Lind, J. S.、Smit, E. F.、Griinberg, K.、Senan, S.、Lagerwaard, F. J.(2008)。Fatal interstitial lung disease after erlotinib for non-small cell lung cancer。Journal of Thoracic Oncology，3(9)，1050-1053。 | | 3. | Tsubata, Y.、Hamada, A.、Sutani, A.、Isobe, T.(2012)。Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly nonsmall-cell lung cancer patient。Journal of Cancer Research & Therapeutics，8(1)，154-156。 | | 4. | Cohen, M. H.、Williams, G. A.、Sridhara, R.、Chen, G.、Pazdur, R.(2003)。FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets。The Oncologist，8(4)，303-306。 | | 5. | 施俞寧、邱昭華、蔡俊明、彭瑞麟(20050400)。Interstitial Pneumonia during Gefitinib Treatment of Non-Small-Cell Lung Cancer。中華醫學會雜誌，68(4)，183-186+CA33。 延伸查詢 | | 6. | Shepherd, F. A.、Rodrigues, Pereira J.、Ciuleanu, T.、Tan, E. H.、Hirsh, V.、Thongprasert, S.(2005)。Erlotinib in Previously Treated Non-Small-Cell Lung Cancer。New England Journal of Medicine，353(2)，123-132。 | | 7. | Del Castillo, Y.、Espinosa, P.、Bodi, F.、Alcega, R.、Munoz, E.、Rabasso, C.(2010)。Interstitial lung disease associated to erlotinib treatment: a case report。Cases Journal，3，59。 | | 8. | Vahid, B.、Marik, P. E.(2008)。Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors。Chest，133(2)，528-538。 | | 9. | Ando, M.、Okamoto, I.、Yamamoto, N.、Takeda, K.、Tamura, K.、Seto, T.(2006)。Predictive Factors for Interstitial Lung Disease, Antitumor。Journal of Clinical Oncology，24(16)，2549-2556。 | | 10. | Chou, C. L.、Ko, H. W.、Wang, C. W.、Yu, C. T.、Kuo, H. P.、Huang, C. D.(2010)。Erlotinib-associated near-fetal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma。Chang Gung Medical Journal，33，100-105。 | | 11. | Hidalgo, M.、Siu, L. L.、Nemunaitis. J.、Rizzo. J.、Hammond. L. A.、Takimoto, C.(2001)。Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies。Journal of Clinical Oncology，19(13)，3267-3279。 | | 12. | Higenbottam, T.、Kuwano, K.、Nemery, B.、Fujita, Y.(2004)。Understanding the mechanisms of drug-associated interstitial lung disease。British Journal of Cancer，91(S2)，31-37。 | | 13. | Makris, D.、Scherpereel, A.、Copin, M. C.、Colin, G.、Brun, L.、Lafitte, J. J.(2007)。Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer。BMC Cancer，7，150。 | | 14. | Liu, V.、White, D. A.、Zakowski, M. F.、Travis, W.、Kris, M. G.、Ginsberg, M. S.(2007)。Pulmonary Toxicity Associated With Erlotinib。Chest，132(3)，1042-1044。 | | 15. | Taj, A.、Kanjwal, S.、Hammersley, J. R.(2011)。New-Onset Acute Interstitial Lung Disease After Treatment With Erlotinib in a Patient With Metastatic Squamous Cell Carcinoma of the Lung。American Journal of Therapeutics，18(1)，19-21。 | | 16. | ter Heine, R.、van den Bosch, R. T.、Lankheet, N. A.、Schaefer-Prokop, C. M.、Beijnen, J. H.、Staaks, G. H.(2012)。Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature。Lung Cancer，75(3)，391-397。 | | 17. | Rudin, C. M.、Liu, W.、Desai, A.、Kaixison, T.、Jiang, X.、Janisch, L.(2008)。Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity。Journal of Clinical Oncology，26(7)，1119-1127。 | |